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Abstract
Introduction Peripheral blood stem cells mobilized by
granulocyte colony-stimulating factor (G-CSF) from heal-
thy donors are commonly used for allogeneic stem cell
transplantation. The effect of G-CSF administration on
global serum metabolite profiles has not been investigated
before.
Objectives This study aims to examine the systemic
metabolomic profiles prior to and following administration
of G-CSF in healthy adults.
Methods Blood samples were collected from 15 healthy
stem cell donors prior to and after administration of G-CSF
10 lg/kg/day for 4 days. Using a non-targeted metabo-
lomics approach, metabolite levels in serum were deter-
mined using ultrahigh performance liquid chromatography-
tandem mass spectrometry and gas chromatography/mass
spectrometry.
Results Comparison of the metabolite profiles of donors
before and after G-CSF treatment revealed 239 metabolites
that were significantly altered. The major changes of the
metabolite profiles following G-CSF administration inclu-
ded alteration of several fatty acids, including increased
levels of several medium and long-chain fatty acids, as
well as polyunsaturated fatty acids; while there were lower
levels of other lipid metabolites such as phospholipids,
lysolipids, sphingolipids. Furthermore, there were signifi-
cantly lower levels of several amino acids and/or their
metabolites, including several amino acids with known
immunoregulatory functions (methionine, tryptophan,
valine). Lastly, the levels of several nucleotides and
nucleotide metabolites (guanosine, adenosine, inosine)
were also decreased after G-CSF administration, while
methylated products were increased. Some of these altered
products/metabolites may potentially have angioregulatory
effects whereas others may suggest altered intracellular
epigenetic regulation.
Conclusion Our results show that G-CSF treatment alters
biochemical serum profiles, in particular amino acid, lipid
and nucleotide metabolism. Additional studies are needed
to further evaluate the relevance of these changes in
healthy donors.
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1 Introduction
Peripheral blood stem cell (PBSC) grafts are commonly
used for allogeneic hematopoietic stem cell transplantation
for a wide range of hematologic malignancies. These grafts
are generally prepared by administration of granulocyte
colony-stimulating factor (G-CSF) to healthy donors which
mobilizes hematopoietic stem cells (HSCs) into the blood
before cells are harvested by leukapheresis. The clinical
advantage of using PBSCs compared to bone marrow grafts
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includes accelerated neutrophil engraftment, which
increases the likelihood to engraft, and in addition PBSC
allografts contain a much larger number of T-cells com-
pared to bone marrow grafts, which has been correlated
with better outcome (Malard et al. 2016; Pabst et al. 2007;
Rezvani et al. 2006).
The HSC mobilizing agent G-CSF is a glycoprotein with
multiple functions, including effects on the production,
migration, differentiation and proliferation of neutrophils,
as well as affecting adaptive immune responses (Bendall
and Bradstock 2014; Panopoulos and Watowich 2008).
G-CSF may have both direct and indirect effects on
immune cells, including monocytes, granulocytes, T-cells
and dendritic cells, and can also alter the expression of
various soluble factors, including cytokines, metallopro-
teinases and adhesion molecules which may themselves
contribute to effects induced by G-CSF (Rutella et al.
2005). Recently, various metabolites and metabolic path-
ways have been found to be involved in cell signaling, also
among immune cells; e.g. both amino acids as well as their
metabolites can bind to specific receptors on immuno-
competent cells and thereby induce activation and/or dif-
ferentiation of these cells (Buck et al. 2015). Furthermore,
certain metabolites have a key role in fundamental meta-
bolic pathways, such as glycolysis or lipid metabolism, and
their availability may thus affect immune cell functions. As
reviewed by Buck et al. (2015), cellular metabolism is
important in the regulation of immunocompetent cell
growth, e.g. differentiation and activation of T-cells. Thus,
the availability and uptake of metabolites may potentially
affect immune cell fate. In this aspect, metabolomics has
emerged as a powerful tool to identify and characterize the
low molecular mass composition of biological samples. In
this exploratory study, we therefore used non-targeted
metabolomics to investigate the early effects of in vivo
G-CSF treatment on the global serum metabolite profile of
healthy stem cell donors.
2 Materials and methods
2.1 Stem cell donors and mobilization
The study was approved by the local ethics committee
(REK Vest, 2011/996 and 2011/1237) and all samples were
collected after written informed consent. Blood samples
were collected from 15 consecutive healthy HLA-matched
related allogeneic stem cell donors (10 males and 5
females), with a mean age of 47 years (range 25–64 years)
(Table 1). Donors received the human non-glycosylated
G-CSF analog Filgrastim (r-metHuG-CSF, Neupogen,
Amgen) or Tevagrastim (biosimilar Filgrastim) in a dose of
5.4 lg/kg body weight (range 4.1–6.7 lg/kg) twice daily
subcutaneously for four days to induce stem cell mobi-
lization. Our hospital is responsible for all allogeneic stem
cell transplantations in a defined geographic area, and this
study included a consecutive group of donors younger than
65 years of age and achieving pre-harvest CD34? cell
counts above 15 9 103/L. Thus, our donors should be
regarded as representative of healthy adult stem cell donors
because they are unselected (i.e. consecutive), mobilize
sufficient stem cells for preparation of allografts and their
age is also representative for donors used in routine clinical
practice.
2.2 Processing of blood samples
Venous blood samples were collected into Vacuette Z
Serum Clot Activator tubes with Gel Separator (Greiner
Bio-One GmbH, Kremsmünster, Austria) from donors at
two time points, (i) prior to administration of G-CSF and
(ii) following G-CSF administration just before apheresis
on day 4. All samples were collected at 9 am and were
allowed to coagulate for 30 min at room temperature in
upright position before being centrifuged at 13109g for
10 min at room temperature. The serum supernatants were
immediately apportioned into 0.5 mL aliquots in plastic
cryotubes (NuncTM, Roskilde, Denmark) and stored frozen
at -80C until analysed.
2.3 Analysis of G-CSF levels
Levels of human G-CSF were measured using a Luminex
assay (R&D Systems, Bio-techne, Abingdon, UK), and the
minimal detectable level was 20 pg/mL.
2.4 Analysis of human serum metabolites
All mass spectrometry data were collected at Metabolon
Inc (Durham, NC). Each serum sample was accessioned
into the Metabolon LIMS system and was assigned a
unique identifier by this system which was used to track all
sample handling and results. All samples were prepared
using the automated MicroLab STAR system (Hamilton
Company, Bonaduz, Switzerland). Briefly, samples were
extracted using Metabolon‘s standard solvent extraction
method (Evans et al. 2014). A recovery standard was added
prior to the first step in the extraction process for quality
control purposes. To remove protein, dissociate small
molecules bound to protein or trapped in the precipitated
protein matrix, and to recover chemically diverse
metabolites, proteins were precipitated with methanol
under vigorous shaking for 2 min followed by centrifuga-
tion. The resulting extract was divided into five fractions:
(i) one for analysis by ultrahigh performance liquid chro-
matography–tandem mass spectrometry (UPLC–MS/MS)
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with positive ion mode electrospray ionization, (ii) one for
analysis by UPLC–MS/MS with negative ion mode elec-
trospray ionization, (iii) one for LC polar platform, (iv) one
for analysis by gas chromatography/mass spectrometry
(GC–MS) and (v) one sample was reserved for backup.
Samples were placed briefly on a Zymark TurboVap
(McKinley Scientific, Sparta, NJ, USA) to remove the
organic solvent. Then samples were either stored overnight
under nitrogen for LC or dried under vacuum overnight for
GC, before preparation for analysis. Experimental samples
were randomized across the platform and run with appro-
priate quality control samples spaced evenly among the
injections. Compounds were identified by comparison to
library entries based upon retention time/index, mass to
charge ratio (m/z) and chromatographic data (also MS/MS
spectral data), and peaks were quantified using area-under-
the curve.
2.5 Statistical analyses
Two types of statistical analysis were performed: (1) sig-
nificance tests (t-tests) and (2) classification analysis.
Random Forest analysis is a supervised classification
technique that provides an unbiased estimate of how well
individuals can be classified into each group in a new data
set. Statistical analyses were performed with the program R
(http://cran.r-project.org/).
3 Results
3.1 G-CSF treatment alters the global metabolomic
profile of healthy individuals
Metabolites were analysed in all serum samples collected
from the healthy donors (i) prior to G-CSF administration
and (ii) on day 4 after G-CSF administration. In total, 641
metabolites were identified (for a complete list see Sup-
plementary Table 1), where levels of 239 metabolites were
significantly changed (p B 0.05); 149 metabolites had
increased levels (62%) and 90 metabolites had decreased
levels (38%) after G-CSF administration (Table 2). These
significantly altered metabolites belong mainly to amino
acid and lipid classes, while metabolites associated with
the categories nucleotides, carbohydrates, energy metabo-
lism, cofactors/vitamins and xenobiotics are also present.
Furthermore, 39 of these metabolites have a p
value\ 0.0001 and are involved in amino acid (19/39),
















1 60 F 30 6.1 \20 [15,000 40.2 5.5
2 25 M 24 6.1 \20 13,514 44.4 8.8
3 45 M 25 5.8 242 [15,000 30.4 4.3
4 51 M 47 4.9 37 [15,000 58.8 3.9
5 39 M 30 5.3 72 13,404 108.8 22.4
6 64 M 36 4.1 \20 9495 26.7 3.9
7 54 F 23 5.7 41 [15,000 34.1 5.2
8 25 M 26 5.7 111 [15,000 147.8 15.1
9 46 F 25 4.6 49 3939 57.6 7.2
10 62 M 27 5.6 24 [15,000 97.0 7.2
11 51 M 26 5.1 53 [15,000 17.4 3.1
12 40 F 34 5.3 39 [15,000 66.7 6.8
13 39 M 25 5.5 22 [15,000 111.1 7.8
14 45 F 26 6.7 82 [15,000 55.1 5.6
15 58 M 29 5.1 80 6776 44.7 4.9
Mean 47 29 5.4 61 [13,000 62.7 8.7
Range 25–64 10M/
5F
23–47 4.1–6.7 \20–242 3939–[ 15,000 17.4–147.8 3.1–22.4
M male; F female; BMI body mass index
a G-CSF plasma levels were measured in donor samples collected at clinical examination and after four days of treatment with G-CSF before
apheresis
b CD34? cell counts were done immediately before stem cell harvest and the CD34? stem cell yield estimated per kg donor/weight
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nucleotide (10/39) or lipid (5/39) metabolism (Table 2).
Among the significantly altered levels of metabolites
(n = 239, p B 0.05) we would expect to see approximately
12 metabolites that meet our level of significance criteria
by random chance, however, our data have a low false
discovery rate (FDR) of less than 5% for all metabolites
except one metabolite with 5.1%, indicating a high level of
confidence in the results (Supplementary Table 2). All
significantly altered metabolites (p B 0.05) and their group
mean ratios (before vs. after G-CSF treatment) are shown
in Supplementary Table 2.
We performed a principal component analysis (PCA)
which showed that the samples before and after G-CSF
administration were generally distinguishable from each
other (Fig. 1); one G-CSF treated sample seemed to deviate
from the other samples but no outlier samples were iden-
tified. This exceptional stem cell donor had the highest
total leukocyte and platelet counts in peripheral blood, the
lowest Hb level after G-CSF administration and the lowest
G-CSF plasma level before apheresis, but did not otherwise
differ from the others, and samples from this donor were
included in all our analyses. Taken together, these results
demonstrate that four days of G-CSF administration alters
the systemic metabolomic profile of healthy individuals;
and despite some heterogeneity between donors, an altered
amino acid, lipid and nucleotide metabolism seems to be a
common characteristic.
3.2 Alteration of single metabolites by G-CSF
treatment
Random forest classification was used for further statistical
analyses. Even though there was an overlap between
samples collected before and during G-CSF therapy in the
PCA plot (Fig. 1), the random forest classification
demonstrated that G-CSF treated versus untreated samples
could be distinguished with 97% predictive accuracy based
on their overall metabolite profiles (Fig. 2). The 30 top-
ranking metabolites that contributed most to separation of
the samples are shown where the metabolites are ranked
according to the mean decrease accuracy (%) (Fig. 2).
These metabolites are involved in several pathways, with
the majority of metabolites belonging to amino acid
metabolism (9 metabolites) and nucleotide metabolism (9
metabolites), but lipid (4 metabolites), xenobiotics (3
metabolites), carbohydrate (2 metabolites), cofactors/
Table 2 Metabolite classes significantly altered after G-CSF treatment
Metabolite classes/pathways Total number of
metabolites identified
Number of significantly altered metabolites
P\ 0.05 P\ 0.001 P\ 0.0001
Amino acids 161 75 30 19
Peptide 28 16 1 1
Carbohydrates 25 8 5 2
Energy metabolism 9 2 - -
Lipids 250 78 13 5
Nucleotides 34 21 11 10
Cofactors-vitamins 22 10 4 -
Xenobiotics 112 29 4 2
Total number of metabolites 641 239 68 39
Fig. 1 Principal component analysis (PCA) scores plot based on the
serum metabolome of healthy stem cell donors before and after
G-CSF treatment. An overlap was seen between groups (n = 15 in
each group, open circles before G-CSF treatment, filled circles after
G-CSF treatment), but groups were generally distinguishable from
each other
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vitamin (1 metabolite) and peptides (1 metabolite) were
also included among the 30 top-ranking metabolites in this
analysis.
3.3 Alteration of lipid, amino acid and nucleotide
metabolism by G-CSF treatment
Treatment with G-CSF resulted in altered systemic (i.e.
serum) levels of a wide range of metabolites reflecting an
alteration of different metabolic pathways during this
treatment in healthy individuals:
• Lipid metabolism Among the main metabolites that
distinguished between pre-and post-G-CSF administra-
tion groups, there was a consistent alteration of the
amount of fatty acids indicating altered lipid metabo-
lism (i.e. a change in fatty acid synthesis, lipid
hydrolysis or mitochondrial b-oxidation) (Fig. 3a).
The post-G-CSF group had significantly elevated levels
of several long-chain fatty acids (such as myristate,
palmitate, margarate, and stearate), as well as polyun-
saturated fatty acids (adrenate, linoleate, linolenate,
dihomolinoleate, docosadienoate, docosapentaenoate).
Finally, levels of carnitine-conjugated lipids were
increased.
• Amino acid metabolism was also altered; within the
post-G-CSF samples there was a reduced level of
dipeptides and amino acids including the aromatic
amino acids tryptophan, phenylalanine and tyrosine and
their metabolites, as well as branched-chain amino
acids valine, isoleucine and leucine (Fig. 3b). The
essential amino acid tryptophan can be metabolized by
several pathways to give rise to serotonin or kynur-
enine, and levels of these degradation products as well
as indoleacetate and 3-indoxyl sulfate were all signif-
icantly lower after G-CSF therapy.
• Nucleic acid metabolism Our results show a signifi-
cantly lower level of purine nucleosides, including
guanosine, adenosine and inosine in the post-G-CSF
Fig. 2 Random forest analysis
of the metabolic profiles in
samples taken before and after
administration of G-CSF in
healthy stem cell donors.
Random forest analysis could
distinguish between the
metabolic profiles of the two
groups with a predictive
accuracy of 97%. The variable
importance plot shows the
variable on the y-axis, and their
importance for separation of the
two groups on the x-axis. The
top-ranked 30 metabolites are
thus ordered top-to-bottom as
most- to least-important based
on their importance. The inset
table shows the main signaling
pathways where each metabolite
belongs, reflected by the
different colors in the plot.
Asterisk indicates that the
biochemical name is identified
but has not been confirmed
based on a standard
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samples, indicating altered nucleotide metabolism
(Fig. 3c). Furthermore, several methylated products
were increased.
3.4 G-CSF induced alteration of metabolic
pathways
We performed a metabolomic pathway enrichment analysis
based on significantly altered metabolites (p\ 0.001), to
identify pathways that contribute to the major differences
when comparing samples taken before and after G-CSF
administration (Fig. 4). This analysis identified altered
glycogen metabolism as a major effect of G-CSF treatment,
and metabolites belonging to pathways involved in
nucleotide metabolism and amino sugar/acid metabolism
were also over-represented in samples after G-CSF
treatment.
3.5 The metabolic alterations induced during G-
CSF therapy are not caused by acetaminophen
Musculoskeletal pain and flu-like symptoms are common
during G-CSF therapy (Stroncek et al. 1996), and symp-
tomatic relief can be achieved by acetaminophen (parac-
etamol). The detection of several metabolites of
acetaminophen in the serum of stem cell donors indicates
that paracetamol had been taken by some donors during
G-CSF therapy. We therefore compared the metabolite
Fig. 3 Metabolite pathways
altered after G-CSF
administration among the
classes lipids, amino acids and
nucleotides. The bar charts
show the different amounts of
metabolites belonging to their
different pathways within the
three main classes: a lipid
metabolism, b amino acid
metabolism and c nucleotide
metabolism, where metabolite
levels were either increased
(dark grey colored) or decreased
(light grey)
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profile before and after G-CSF therapy for donors with high
and low/undetectable levels of metabolites involved in
acetaminophen metabolism. When comparing the levels of
the 30 top-ranked metabolites (Fig. 2), we did not find any
significant differences between the donor samples with
high and low/undetectable paracetamol metabolite (data
not shown). Thus, it seems unlikely that the paracetamol
intake has a major impact on the metabolic modulation
during G-CSF therapy.
4 Discussion
In this study, we investigated the early effects of G-CSF
administration on the serum global metabolite profile of
healthy stem cell donors that were younger than 65 years
and had an adequate stem cell mobilization. G-CSF is
mainly used as short-term therapy, generally requiring
4–6 days of treatment, for stem cell mobilization (Bendall
and Bradstock 2014); however, it is also used as long-term
treatment for patients with low-risk myelodysplastic syn-
drome (Jadersten et al. 2005) and especially for patients
with chronic neutropenia (Dale 2016; Dale and Welte
2011; Donadieu et al. 2011; Zeidler et al. 2014). The
suggested initial doses for congenital neutropenia are
3–5 lg/kg that are increased in steps of 5 lg/kg (Dale
2016; Donadieu et al. 2011), thus these G-CSF doses used
in long-term therapy are also comparable to the doses used
in our present study (5 lg/kg twice daily).
Our study included a relatively small number of sam-
ples, but our random forest classification analysis resulted
in 97% predictive accuracy in differentiating the two
groups, indicating that differences due to G-CSF adminis-
tration were readily present. Several of the 30 top-ranking
metabolites shown in Fig. 2 have been reported to be
involved in biological processes such as regulation of
immune responses, inflammation, vascular biology and
epigenetic regulation (see Supplementary Table 3), though
further studies will be needed to see if G-CSF has a long-
term effect on these biological processes. In general, global
metabolomics profiling revealed altered levels of lipids,
amino acids, carbohydrates and nucleotides after adminis-
tration with G-CSF.
One of the strongest changes in our dataset was the
altered lipid metabolism, in particular the significantly
higher levels of long-chain fatty acids as well as carnitine-
conjugated lipids after G-CSF administration, indicating
changes in fatty acid b-oxidation. Long-chain fatty acids
are conjugated to carnitine to facilitate transport across the
mitochondrial membrane, and the increased acyl carnitine
levels may thus suggest increased b-oxidation. Moreover,
glycerol, a marker of lipolysis, was significantly decreased
in the G-CSF treated group. These alterations may be due
to increased fatty acid b-oxidation or alternatively due to
disturbance of fatty acid oxidation resulting in increased
amounts of lipid precursors. In addition, we found a decline
in the serum levels of sphingosine 1-phosphate (S1P) after
G-CSF administration, which is in concordance with
another study that measured S1P levels in donors under-
going G-CSF-induced mobilization (Juarez et al. 2012).
Disruption of fatty acid signaling has been implicated in
mobilization of stem cells, in particular S1P (Ratajczak
Fig. 4 Metabolite pathway
enrichment analysis to identify
pathways enriched after G-CSF
administration in healthy
donors. A pathway enrichment
analysis was done based on
significantly altered metabolites
with p\ 0.001. Only signaling
pathways with an enrichment
value greater than two and at
least two metabolites within
each pathway are shown in the
figure. The most significant
p-values are seen in red, while
the least significant are in yellow
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et al. 2010). To summarize, G-CSF treatment alters fatty
acid metabolism and decreases the systemic levels of fatty
acid metabolites involved in hydrolysis (phospholipid
metabolism and lysolipids) whereas long/medium-chain
fatty acids are generally increased.
In this study we found lower levels of branched chain
amino acids and aromatic amino acids following G-CSF
treatment. Among the aromatic amino acids we found
altered levels of tryptophan and its degradation products
which are shown to be associated with inflammation.
Kynurenine plays a role in modulation of inflammation and
the ratio of kynurenin/tryptophan has been suggested to be
an indicator for the activity of indolamine-2,3-dioxygenase
(IDO) (Widner et al. 1997), which can affect T cell func-
tions. Branched chain amino acids can be substrates for
both energy production and protein synthesis. They can be
metabolized to give rise to intermediates for several
metabolic pathways including the TCA cycle or fatty acid
synthesis. Less amounts of the branched amino acids iso-
leucine, valine and leucine may thus potentially have an
impact on energy metabolism by reduction of available
metabolites. However, in addition to the lower levels of
these amino acids, we also observed a general decrease in
dipeptide levels after G-CSF administration which is sup-
portive of reduced proteolysis.
Previous studies have examined effects of in vivo
administration of G-CSF on normal peripheral blood
mononuclear cells (PBMCs) using whole genome expres-
sion profiling. Changes in global gene expression profiles
were then described both at early time points after G-CSF
administration (up to 5 days) (Hernandez et al. 2005) and
after 2–10 months (Amariglio et al. 2007), and even a year
after G-CSF administration in CD34? progenitor cells
(Baez et al. 2014). These studies have revealed that there
seems to be both early responses to G-CSF, transient
changes that are normalized over time and more long-
lasting changes. In the recent study by Bàez et al., G-CSF-
mobilized hematopoietic progenitors had a difference in
the expression of six microRNAs and even one year after
G-CSF administration over 2424 genes maintained their
altered expression (Baez et al. 2014). Among the differ-
entially expressed genes were genes involved in cellular
growth, cell death and survival, protein synthesis, gene
expression and nucleic acid metabolism. In another study
of twenty stem cell donors, changes of DNA methyltrans-
ferase activity in peripheral blood cells were found after
G-CSF administration, though these changes returned to
baseline within a week after apheresis (Leitner et al. 2014).
Thus, several studies of donor cells suggest epigenetic
changes induced after G-CSF administration in healthy
donors, though none of these studies have investigated the
global metabolite profile of healthy donors after G-CSF
treatment. Accordingly, in our study of the systemic
metabolite profile, we observed altered nucleic acid meta-
bolism by G-CSF therapy, including lower levels of the
purine nucleosides. Furthermore, several methylated
products were increased which could suggest a difference
in methylation potential through treatment with G-CSF.
These results should be interpreted with great care, but
could suggest that G-CSF has the potential to influence
epigenetics.
We have not performed any functional assays to eval-
uate the potential association between metabolites altered
by G-CSF and immunomodulatory effects; however,
G-CSF has been shown to induce several cellular and
immunological changes in donor cells (Anderlini et al.
1996; Shaw et al. 2015), and several of the altered
metabolites found in our study have known immunoregu-
latory and/or angioregulatory effects, or can be markers of
altered regulation of epigenetic/gene expression that may
contribute to the previously described long-lasting effects
after G-CSF therapy (Baez et al. 2014). Altered metabolite
levels may reflect the direct effects of G-CSF on different
immune cell types, affecting cell proliferation, differenti-
ation and function, but also indirect effects through e.g.
upregulation of cytokine production may subsequently
affect cells and lead to altered metabolite levels. G-CSF
binds to the single high-affinity 140 kDa G-CSF receptor
(G-CSFR), which is expressed on myeloid progenitor cells,
mature granulocytes and monocytes, lymphocytes and
endothelial cells (Demetri and Griffin 1991; Franzke et al.
2003) and can activate multiple signaling pathways
including JAK-STAT and ERK/MAPK pathways. How-
ever, the expression of this receptor does not seem to be
required for progenitor mobilization induced by G-CSF
(Liu et al. 2000), and G-CSF-mediated effects may also
occur independent of the G-CSF receptor. Further studies
are needed to explore the mechanism inducing the
metabolite changes after G-CSF treatment and their
potential immunomodulatory effects and/or effects on
other cell functions.
A possible explanation for our findings could be that
they are secondary to an increased proliferation of imma-
ture hematopoietic cells to replace the cells that are lost
from hematopoietic niches to the circulation. However, the
CD34? cell number and the total peripheral blood leuko-
cyte number is controlled daily during stem cell mobi-
lization, and the duration of this altered
compartmentalization of hematopoietic cells is therefore
relatively short (\24 h). Furthermore, the increased levels
of immature hematopoietic cells in the peripheral blood
probably represent a minor part of the overall number of
nucleated bone marrow cells, and one should also
emphasize that the cells have not yet been harvested at the
time of sampling for metabolite analysis. However, we
cannot exclude the possibility that the metabolic changes
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are secondary to an increased proliferation of bone marrow
cells, but if so this is in our opinion most likely caused by
direct G-CSF stimulated proliferation during the whole
treatment period rather than being a compensatory mech-
anism to altered compartmentalization during the last hours
before stem cell harvesting.
Several metabolites classified as xenobiotics were
altered after G-CSF therapy. Many stem cell donors
experience side effects during treatment (Stroncek et al.
1996), and acetaminophen is then recommended for pain
relief. Some altered metabolites belonging to the xenobi-
otic class are a direct result of acetaminophen usage, and in
our opinion some of the other metabolite changes may be
associated with treatment toxicity and/or altered gastroin-
testinal function.
5 Concluding remarks
In totum, our results show that the level of several
metabolites changed after G-CSF administration, primarily
there were (i) increased levels of lipids indicating altered
fatty acid metabolism, (ii) increased levels of methylated
nucleosides, (iii) changes associated with energy metabo-
lism, and (iv) altered levels of amino acids, including
reduced peptide levels indicating decreased proteolysis and
altered levels of acetylated peptides. Long-term follow up
studies have concluded that the use of G-CSF to mobilize
stem cells appears to be safe (Shaw et al. 2015). Our study
shows distinct differences in the metabolite profiles
between healthy donors before and after G-CSF adminis-
tration; however this is only a snapshot of the metabolomic
profile of donors at an early time point after G-CSF
administration and further studies should examine the
metabolite profiles over time, using a larger set of donors,
to clarify whether G-CSF also has long-term effects on
metabolite profiles and/or if patients on long-term G-CSF
therapy should be monitored with regard to metabolic
abnormalities.
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